Aquinox Pharmaceuticals ROE 2013-2018 | AQXP

Current and historical return on equity (ROE) values for Aquinox Pharmaceuticals (AQXP) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Aquinox Pharmaceuticals ROE for the three months ending December 31, 2018 was -38.77%.
Aquinox Pharmaceuticals ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2018-12-31 $-0.03B $0.07B -39.14%
2018-09-30 $-0.04B $0.08B -48.73%
2018-06-30 $-0.04B $0.09B -41.03%
2018-03-31 $-0.06B $0.09B -53.77%
2017-12-31 $-0.05B $0.10B -42.11%
2017-09-30 $-0.05B $0.11B -34.55%
2017-06-30 $-0.04B $0.13B -29.18%
2017-03-31 $-0.04B $0.14B -28.73%
2016-12-31 $-0.04B $0.15B -29.96%
2016-09-30 $-0.03B $0.16B -28.01%
2016-06-30 $-0.03B $0.09B -27.88%
2016-03-31 $-0.02B $0.10B -26.29%
2015-12-31 $-0.02B $0.11B -31.65%
2015-09-30 $-0.02B $0.11B -46.60%
2015-06-30 $-0.03B $0.03B -73.53%
2015-03-31 $-0.03B $0.03B -62.50%
2014-12-31 $-0.02B $0.04B -49.73%
2014-09-30 $-0.02B $0.04B -48.41%
2014-06-30 $-0.02B $0.05B -63.72%
2014-03-31 $-0.02B $0.06B -95.24%
2013-12-31 $-0.01B $0.01B -700.00%
2013-09-30 $-0.01B $0.00B -4000.00%
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.064B $0.025B
Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company discovers and develops oral drug candidates to treat inflammation and cancer. Aquinox Pharmaceuticals, Inc. is headquartered in Vancouver, Canada.
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $50.172B 9.03
Teva Pharmaceutical Industries (TEVA) Israel $16.921B 5.84
Mylan (MYL) United Kingdom $14.539B 6.15
Bausch Health Cos (BHC) Canada $8.584B 6.10
Dr Reddy's Laboratories (RDY) India $6.489B 25.88
Supernus Pharmaceuticals (SUPN) United States $2.008B 18.63
Mallinckrodt Public Limited Company (MNK) United Kingdom $1.896B 3.08
Homology Medicines (FIXX) United States $1.048B 0.00
Amphastar Pharmaceuticals (AMPH) United States $0.953B 88.57
CymaBay Therapeutics (CBAY) United States $0.794B 0.00
Voyager Therapeutics (VYGR) United States $0.616B 0.00
Assembly Biosciences (ASMB) United States $0.502B 0.00
Akorn (AKRX) United States $0.432B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.389B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.215B 0.00
Sol-Gel Technologies (SLGL) Israel $0.132B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.102B 0.00
Acasti Pharma (ACST) Canada $0.083B 0.00
Teligent (TLGT) United States $0.070B 0.00
Agile Therapeutics (AGRX) United States $0.069B 0.00
Evoke Pharma (EVOK) United States $0.025B 0.00
Aevi Genomic Medicine (GNMX) United States $0.015B 0.00
China Pharma Holdings (CPHI) China $0.014B 0.00